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Abstract
Background—Biliopancreatic-type postcholecystectomy pain, without significant abnormalities 
on imaging and laboratory test results, has been categorized as “suspected” sphincter of Oddi 
dysfunction (SOD) type III. Clinical predictors of “manometric” SOD are important to avoid 
unnecessary ERCP, but are unknown.
Objective—To assess which clinical factors are associated with abnormal sphincter of Oddi 
manometry (SOM).
Design—Prospective, cross-sectional.
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Patients—A total of 214 patients with suspected SOD type III underwent ERCP and pancreatic 
SOM (pSOM; 85% dual SOM), at 7 U.S. centers (from August 2008 to March 2012) as part of a 
randomized trial.
Interventions—Pain and gallbladder descriptors, psychosocial/functional disorder 
questionnaires.
Main Outcome Measurements—Abnormal SOM findings. Univariate and multivariate 
analyses assessed associations between clinical characteristics and outcome.
Results—The cohort was 92% female with a mean age of 38 years. Baseline pancreatic enzymes 
were increased in 5%; 9% had minor liver enzyme abnormalities. Pain was in the right upper 
quadrant (RUQ) in 90% (48% also epigastric); 51% reported daily abdominal discomfort. Fifty-six 
took narcotics an average of 33 days (of the past 90 days). Less than 10% experienced depression 
or anxiety. Functional disorders were common. At ERCP, 64% had abnormal pSOM findings 
(34% both sphincters, 21% biliary normal), 36% had normal pSOM findings, and 75% had at least 
abnormal 1 sphincter. Demographic factors, gallbladder pathology, increased pancreatobiliary 
enzymes, functional disorders, and pain patterns did not predict abnormal SOM findings. Anxiety, 
depression, and poorer coping were more common in patients with normal SOM findings (not 
significant on multivariate analysis).
Limitations—Generalizability.
Conclusions—Patient and pain factors and psychological comorbidity do not predict SOM 
results at ERCP in suspected type III SOD. (Clinical Trial registration number: NCT00688662.) 
(Gastrointest Endosc 2014;79:765-72.)
Approximately 700,000 cholecystectomies are performed each year in the United States for 
abdominal pain attributed to gallstones and/or biliary dyskinesia.1 Approximately 10% of 
these patients present post-cholecystectomy with continued biliary-type pain; most of these 
patients are women.2,3 The most likely explanation for continued pain is that the symptoms 
were not due to the biliary tree in the first place. However, in some patients, a functional 
disorder of the sphincter of Oddi is suspected, presumed to be caused by spasm and/or 
stenosis of the major papilla (sphincter of Oddi dysfunction [SOD]).4,5
Noninvasive tests for SOD have been proven in shamcontrolled randomized trials to be 
inaccurate and to not correlate with outcomes.6,7 However, in contrast, ERCP with sphincter 
of Oddi manometry (SOM) does predict response, in so-called type II SOD patients (those 
with either laboratory or imaging evidence of obstruction, but not both). Suspected type II 
SOD patients undergoing sphincterotomy responded (significant improvement in pain) 
approximately twice as often if their manometry results were positive for basal hypertension, 
compared with when manometry results were normal, in both the small American and 
Australian randomized trials.6,7 Sphincter “dyskinesia,” encompassing other manometric 
criteria not commonly used in the United States, was not predictive.7 However, ERCP has a 
10% to 20% pancreatitis rate and a 1 in 1000 mortality rate in suspected SOD patients, and 
type III SOD patients (normal laboratory test and imaging results) have tremendous overlap 
with functional epigastric pain syndromes8 and are believed to be unlikely to benefit from 
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ERCP. Therefore, clinical predictors of manometric SOD are important in order to avoid 
unnecessary ERCP, but these data are lacking, particularly in type III SOD.
Anecdotally, primary caregivers and specialists generally believe that psychological 
disturbances, coexisting irritable bowel syndrome, narcotic use, previous gallbladder 
objective pathology, and minor changes in laboratory test results help them to predict the 
presence or absence of objective findings of SOD at ERCP in patients with unexplained 
abdominal pain. This may be more personal bias than science because an Australian study 
(N = 72) found no association between clinical and psychological factors and basal 
hypertension at SOM,9 and Winstead and Wilcox10 found psychological disturbances to be 
either as common or less common in patients undergoing SOM for pain compared with 
patients undergoing ERCP for recurrent pancreatitis. Many also believe that objective 
imaging and laboratory tests are important, yet both randomized trials and a retrospective 
review found no evidence that provocation tests, duct dilation, or enzyme elevations 
predicted response to therapy.6,7,11 Freeman et al11 found that only abnormal pancreas 
SOM, along with 3 other factors (gastroparesis, daily opioids, and older than 40 years of 
age), predicted response. The EPISOD (Evaluating Predictors and Interventions in Sphincter 
of Oddi Dysfunction) trial is a National Institute of Diabetes and Digestive and Kidney 
Diseases–sponsored randomized, sham-controlled study representing the largest prospective 
cohort of suspected type III SOD patients and a unique opportunity to identify these 
predictors. The aim of this analysis was to assess whether suspected SOD patients’ baseline 
characteristics predict pancreatic/biliary SOM (pSOM/bSOM) abnormalities.
METHODS
Patients
Seven centers in the United States prospectively recruited postcholecystectomy patients with 
epigastric or RUQ pain causing marked disability but without overt imaging or laboratory 
test evidence of biliary obstruction or pancreatitis, meeting modified Rome III criteria for 
functional biliary/pancreatic pain and not responding to acid antisecretories and 
antispasmodics,12 to participate in a sham-controlled, randomized trial of sphincterotomy at 
ERCP from August 2008 to March 2012. Institutional review board approval was obtained 
at each center. All authors had access to the study data and had reviewed and approved the 
final manuscript.
The EPISOD study protocol has been reported in detail and is registered on clinicaltrials.gov 
(NCT00688662).12 Eligibility criteria required patients to be 18 to 65 years of age with 
significant pain-related disability after cholecystectomy, with no pancreatic pathology or 
previous sphincter treatment, and not taking narcotics daily. Additional criteria included 
pain characteristics consistent with biliary SOD as defined by the ROME III criteria 
modified to include patients with daily abdominal discomfort in addition to episodes of pain, 
more than 11 days of disability due to pain in the 3 months before study enrollment, results 
of laboratory tests performed within 6 months of the baseline visit could not be more than 2 
times the upper limit of normal for direct bilirubin, alkaline phosphatase, amylase, and 
lipase and no more than 3 times the upper limit of normal for transaminases; patients 
receiving antidepressants for pain control must have been taking them for a minimum of 1 
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month before the baseline assessment, and patients receiving psychopharmacological 
treatment must have been on a stable dose for at least 6 weeks. Patients were excluded if 
they had significant psychiatric disorders (psychotic and bipolar disorders), current 
substance abuse, eating disorders, severe depression [as defined by a Beck Depression 
Inventory II score of ≥22), or suicidal risk (assessed by Beck Depression Inventory II and 
the Mini International Neuropsychiatric Interview questionnaires).
When Rome III definitions are used, the main difference between functional abdominal pain 
and biliary pain is that the former is continuous or nearly continuous, with no or only 
occasional associations with physiologic events (eg, eating). The Rome III definitions for 
biliary pain versus the epigastric pain syndrome subset of functional dyspepsia are similar, 
except that the latter can be burning in quality and the former must be severe enough to 
bring one to an emergency department; must not be relieved by bowel movements, postural 
change, or antacids; and may radiate to the back or right subscapular region and/or be 
associated with nausea and vomiting.
Data on candidate predictors
We studied the following potential predictors: age, sex, race, location of pain, 
characterization of pain (including constant versus intermittent, daily vs nondaily 
discomfort), narcotic use, timing and pain-relief duration of cholecystectomy, 
precholecystectomy gallbladder findings and pathology, psychological comorbidity (anxiety 
and depression measured by Hospital Anxiety and Depression Scale anxiety and depression 
subscales and the Beck Depression Inventory II), concurrent functional disorders (Rome III), 
Coping Strategies Questionnaire-Catastrophizing scale (CSQ-CAT), and quality of life 
(SF-36). Pain-related disability was quantified by the RAPID (recurrent abdominal pain 
intensity and disability) scale validated specifically for the quantification of the combination 
of intermittent and chronic pain in these patients adapted from the Migraine Disability 
Assessment migraine pain score.13
Manometry outcome assessment
After successful pSOM with a triple-lumen perfusion catheter (final inclusion criteria), 
patients were enrolled in a randomized trial of sphincterotomy or sham at 7 U.S. Centers 
(August 2008-March 2012), even if manometry findings were normal. Manometric 
pancreatic SOD (pSOD) was defined a priori as a positive pancreatic SOM (pSOM) (basal 
pressures >40 mm Hg) in both proximal and distal leads. Biliary SOM (bSOM) was 
attempted and documented when feasible without increasing the risk of the procedure (eg, 
risking losing cannulation).
Statistical analysis
SAS software version 9.2 (SAS Institute Inc, Cary, NC) was used to perform statistical 
analyses. Baseline variables were described by using count and percentage for categorical 
data or mean and standard deviation (SD) for continuous normal data. For variables 
identified as clinically relevant, univariate tests were performed using the χ2 and Student t 
tests to assess the association with abnormal pSOM. Multivariate logistic regression analysis 
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was conducted for predictors with P < .10 on univariate analysis. Secondary analyses to 
predict “any SOD” (any positive SOM) were also performed.
RESULTS
Demographic and patient characteristics
A total of 214 patients were randomized after successful pSOM. A nonrandomized cohort of 
patients refusing randomization was also followed (N = 72) with demographic 
characteristics comparable to those of the randomized cohort.
As anticipated, more than 90% of randomized subjects were women, and mean age was 38 
years (SD 11) (Table 1). Less than 10% had minor pancreatobiliary enzyme increases 
documented before enrollment, but otherwise did not meet exclusion thresholds for those 
laboratory test results. Per protocol, all had undergone previous upper endoscopy that did 
not explain the symptoms and had trials of antacids and antispasmodics that failed. To assess 
the pre-enrollment imaging criteria for duct size and pancreatobiliary pathology, 54% had 
undergone an abdominal US scan, 77% had undergone CT, 61% had undergone MRCP, and 
24% had undergone EUS. The final assessment for exclusion criteria included a lack of 
significant biliary or pancreatic pathology (or divisum) at their ERCP.
Almost half had gallstones at cholecystectomy and just more than half had abnormal 
gallbladder scintigraphy findings (biliary dyskinesia). Cholecystectomies occurred an 
average of 4 years before enrollment, and median pain response was 1 month, with a wide 
range. A third met criteria for irritable bowel syndrome, and 1 of 5 had functional abdominal 
pain. Twenty percent had been tested for gastroparesis, and 10% of those had a positive 
gastric emptying study.
Less than 10% met criteria for an anxiety disorder (2.3%, panic disorder and/or agoraphobia; 
6.5%, generalized anxiety disorder) at baseline and less than 10% had current depression 
(major depressive episode or dysthymia). The average CSQ-CAT catastrophizing (lack of 
coping) score was 7.6 (comparable to healthy volunteers, before and after experimental pain: 
range 6.8-7.6 [SD 4-5]).14
Most patients had RUQ pain, with or without more central epigastric pain, whereas 10% had 
central pain alone. The epigastric pain was worsened by meals in just more than half of 
patients. Daily abdominal pain was reported by half of the enrolled population; one fourth 
reported taking narcotics, using narcotics 1 in 3 days on average (mean just more than 30 of 
the 90 days before enrollment). RAPID scores were high (O80, grade 4 of 4), and quality of 
life by the SF-36 was more than 1 SD lower than a normal population for the physical 
component, but comparable to the normal population for the mental component.
Manometry results
Of the 214 subjects, 64% had abnormal pSOM findings (ie, pSOD). This included 34% with 
both sphincters abnormal, 21% with pSOM abnormal but bSOM normal (isolated pSOD), 
and 9% who did not have attempted or successful bSOM. The other 36% had normal pSOM 
findings: 19% had both sphincters assessed and both were found to be normal; in 6%, the 
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biliary sphincter was not assessed, and in the remaining 11%, bSOM alone findings were 
abnormal (isolated biliary SOD). Including the 11% with abnormal findings on bSOM 
alone, the proportion with “any SOD” was 64% + 11% = 75% (n = 161). Of those 182 who 
underwent successful bSOM, 53% of bSOM findings were abnormal.
Clinical associations/correlations with manometry
Age, sex, previous gallbladder pathology, minor liver/pancreatic enzyme increases, pain 
location, meal relatedness, and daily (vs nondaily/intermittent) pattern did not predict 
abnormal pSOM findings (Table 1). The inability to finish a meal at least daily or weekly 
and claiming feeling uncomfortably full after a meal were also not different between groups 
(data not shown). There was a numerically higher proportion of narcotic users in the normal 
pSOM findings group, but this was not statistically significant. Minor liver enzyme 
increases were actually slightly less common (not significantly) in the manometric pSOD 
group. Coexisting depression and/or other functional bowel or gastric motility disorders did 
not correlate with manometric pSOD. Limited data (n = 127) were available on the influence 
of occupational background (perhaps influencing doctor-seeking behavior), but health-care 
workers were equally common in normal and abnormal pSOM findings groups (30% in 
each).
The lack of predictive associations of pain type, functional or motility disease, psychological 
comorbidity, and narcotic use with SOD also generally held true for “any SOD” (Table 2) or 
biliary SOD (Table 3). Age was slightly older in the any-SOM-abnormal finding group (39 
vs 36 years; P = .04), but this is not likely clinically relevant. CSQ-CAT catastrophizing 
score (poor coping) was higher (6.8 vs 8.6; P = .05), and anxiety (6% vs 14%; P = .07) and 
depression disorders (6% vs 11%; P = .28) were more common in patients with normal 
bSOM findings; a similar nonsignificant trend for these factors was seen in the any-SOM-
abnormal finding versus both-SOM-normal finding analysis. CSQ-CAT catastrophizing 
scores and RAPID scores were also assessed as quartiles, but no significant trends were seen 
(data not shown).
On multivariate analysis, none of the identified variables (age, baseline RAPID score, and 
catastrophizing score) for predicting any-positive-SOM finding were statistically significant. 
Similar results were found when modeling bSOM for the MINI anxiety and catastrophizing 
score. Also, although 40 mm Hg is the standard threshold for sphincter basal pressure 
normality and was the one defined a priori, it is notable that similar results were seen when 
exploring 60- and 100-mm Hg cutoffs for manometry; in fact, the few borderline trends seen 
with the standard definition were no longer significant, with higher P values (data not 
shown).
DISCUSSION
Contrary to perceptions by caregivers, many of the factors that are commonly thought to be 
“objective” (abnormal results on laboratory tests, stones at previous cholecystectomy), 
“typical” (intermittent, nondaily, RUQ) pain, and “nonfunctional” (lack of other functional 
disorders, depression, anxiety, and narcotic use) disease status do not predict sphincter 
manometry results at ERCP in patients suspected of having type III SOD. At present, 
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sphincter manometry is our best predictor of pain response after sphincterotomy, based on 
data extrapolated from prospective, randomized trials in type II SOD. Given the risks of 
ERCP with manometry, it was hoped that clinical criteria could predict who would benefit 
from the procedure by predicting manometry results. However, our results are disappointing; 
there does not appear to be a noninvasive clinical way to predict which of these patients are 
best suited for the risks of an ERCP. There was only a weak signal in univariate analyses for 
a higher rate of anxiety, depression, and poor coping (catastrophizing) in patients with 
normal manometry results (ie, those with lack of objective, manometrically confirmed 
SOD), particularly for bSOM; these were not significant on multivariate analysis.
The strengths of this study are the rigorous inclusion criteria, including manometry criteria 
standardized across centers, and pSOM in all patients. As well, the in-depth clinical and 
psychological questionnaires are unprecedented in this population. The weaknesses include 
the lack of bSOM in some patients. In addition, it remains to be seen whether manometric 
SOD in type III SOD patients is as predictive of response as it was in the 2 trials mainly 
including type II SOD patients. The increase in lipase or liver enzymes, especially if only on 
1 or 2 occasions, and often with a high prevalence of nonalcoholic fatty liver disease 
interfering with the interpretation of a mild liver enzyme increase, is a source of 
controversy. Some may argue that the small percentage of patients with these mild 
abnormalities should have been termed SOD type II. However, we only accepted minor 
increases, and they were not predictive of SOD. In addition, a patient with several months of 
abdominal pain, with repeatedly normal results on laboratory tests, and with only 1 set with 
minor increases is arguably not in the spirit of the type II SOD designation.
Provocation and nuclear imaging tests were not mandated in this study and were seldom, if 
ever, done before ERCP. Although 1 study showed promise for scintigraphic drainage tests 
in predicting biliary SOD (with a high proportion of patients with dilated biliary trees),15 
this has not been reproduced by others: Darweesch et al,16 67% sensitivity; Corazziari et 
al,17 50% specificity; and Craig et al,18 25% to 38% sensitivity. It is not surprising that 
patients with normal-size bile ducts will likely have different drainage determinants and that 
biliary scintigraphy is not likely to predict pancreatic sphincter abnormalities well. As stated 
earlier, biliary provocation tests were not predictive of outcome in 2 randomized trials with 
morphine and neostigmine/prostigmine,6,7 despite some promise shown many years earlier 
of more than 90% sensitivity and specificity.19 Cholecystokinin-stimulated magnetic 
resonance imaging (58% specificity),20 secretin-stimulated magnetic resonance imaging 
(27% sensitivity),21 and secretin-stimulated EUS (57% sensitivity with intravenous 
secretin)22 have all performed poorly. Fibrotic criteria on EUS did not seem to predict 
manometric SOD at our institution.23 Botulinum toxin injected near the sphincter has been 
shown in some preliminary studies to potentially predict response to therapy,24,25 but 
defining response and differentiating brief placebo responses from real responses is difficult. 
In addition, it had a high rate of post-ERCP pancreatitis in 1 study.26
In summary, although the perception has been that using patient characteristics, including 
functional and psychological comorbidities, previous gallbladder pathology, and more 
typical pain patterns, can predict who will have objective (manometrically confirmed) SOD 
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during ERCP, this does not appear to be the case. Selecting patients for whom ERCP is 
appropriate in type III SOD remains difficult.
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• Selecting patients for ERCP and manometry in suspected type III sphincter of 
Oddi dysfunction, without obvious obstruction on laboratory tests/imaging, 
should not be biased by the coexistence of irritable bowel syndrome, depression 
or anxiety, or objective previous gallbladder disease because these do not 
predict manometry results.
• Classic pain (intermittent, meal related) features are equally likely to be 
manometry positive than more constant epigastric and right upper quadrant pain 
syndromes; the arbitrary criterion regarding biliopancreatic pain not occurring 
daily in ROME III may not be appropriate.
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TABLE 1
Prevalence of candidate baseline predictors in patients with and without abnormal pancreatic manometry
pSOM abnormal





Demographic factors and laboratory tests
 Sex, % female 93 90 92 .32
 Age, y, mean (SD) 39 (11.1) 38 (10.9) 38 (11.0) .67
 Elevated amylase, % 1.5 1 1 1.00
 Elevated lipase, % 5 4 5 1.00
 Liver enzyme abnormalities, % 7 13 9 .11
Gallbladder details
 Gallstones at cholecystectomy, % 47 48 47 .32
 Abnormal nuclear scan findings before
 cholecystectomy, no. (%)
54 (81) 50 (48) 53 (129) .48
 Years since cholecystectomy, mean (SD) 4.5 (5.0) 4.1 (6.1) 4.2 (5.4) .88
 Days of pain response after cholecystectomy
 (median (min, max))
31 (0, 7300) 55 (0, 14,965) 31 (0, 14,965) .55
Functional/psychological comorbidity
 Irritable bowel syndrome, Rome III, % 39 42 40 .76
 Functional abdominal pain, Rome III, % 20 18 19 .79
 Abnormal gastric emptying study, no. (%) 12.5 (24) 10 (20) 11 (44) .79
 Catastrophizing, CSQ-CAT, mean (SD) 7.5 (6.9) 7.8 (6.4) 7.6 (6.7) .54
 MINI depressive disorder, % 7 9 8 .64
 MINI anxiety disorder, % 9 9 9 .93
Pain pattern, disability, quality of life
 RUQ pain only, % 39 48 42
 Central epigastric pain only, % 10 10 10 .37
 Both RUQ and epigastric pain, % 51 42 48
 Epigastric pain worsened by meals, no. (%) 56 (95) 46 (46) 53 (141) .11
 Daily discomfort for the past month, % 55 46 51 .42
 Narcotic use, % 23 31 26 .46
 Days taking narcotics, mean (SD) 33 (26.8) 33 (28.2) 33 (27.1) .93
 RAPID score (pain-related disability) (SD) 85.7 (55.4) 82.5 (62.9)) 84.5 (58.1) .37
 SF-36 physical score (SD) 38.3 (8.3) 39.4 (7.0) 38.7 (7.9) .47
 SF-36 mental score (SD) 48.1 (9.8) 49.8 (9.2) 48.7 (9.6) .25
pSOM, Pancreatic sphincter of Oddi manometry; SD, standard deviation; CSQ-CAT, Coping Strategies Questionnaire–Catastrophizing Scale; MINI, 
Mini International Neuropsychiatric Interview; RUQ, right upper quadrant; RAPID, recurrent abdominal pain intensity and disability.
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TABLE 2
Prevalence of candidate baseline predictors in patients with and without any (pancreatic/biliary) abnormal 
SOM
Any SOM abnormal
findings, (n = 161, 75%)
Normal SOM findings
in both (n = 53, 25%)
Total sample
(N = 214) P value
Demographic factors and laboratory tests
 Sex, % female 93 91 92 .77
 Age, y, mean (SD) 39 (11.0) 36 (10.5) 38 (11.0) .04
 Elevated amylase, % 1 2 1 1.00
 Elevated lipase, % 5 4 5 1.00
 Liver enzyme abnormalities, % 8 11 9 .58
Gallbladder details
 Gallstones at cholecystectomy, % 48 45 47 .67
 Abnormal nuclear scan before cholecystectomy,
 no. (%)
52 (94) 54 (35) 53 (129) .81
 Years since cholecystectomy (SD) 4.5 (5.9) 3.3 (3.6) 4.2 (5.4) .91
 Days of pain response after cholecystectomy,
 median (min, max)
31 (0, 14,965) 61 (0, 5475) 31 (0, 14,965) .48
 Functional/psychological comorbidity
 Irritable bowel syndrome, Rome III, % 39 43 40 .58
 Functional abdominal pain, Rome III, % 19 21 19 .73
 Abnormal gastric emptying study, no. (%) 10 (29) 13 (15) 11 (44) 1.00
 Catastrophizing score (CSQ-CAT), mean (SD) 7.2 (6.7) 8.7 (6.6) 7.6 (6.7) .09
 MINI depressive disorder, % 7 11 8 .38
 MINI anxiety disorder, % 8 11 9 .58
Pain pattern, disability, quality of life
 RUQ pain only, % 40 49 42
 Central epigastric pain only, % 10 11 10 .40
 Both RUQ and epigastric pain, % 50 40 48
 Epigastric pain worsened by meals, no. (%) 54 (109) 47 (32) 53 (141) .33
 Daily discomfort for the last month, % 52 51 51 .52
 Narcotic use, % 26 28 26 .85
Days taking narcotics, mean (SD) 34 (27.1) 30 (28.0) 33 (27.1) .63
RAPID score, mean (SD) 87.6 (57.1) 75.3 (60.5) 84.5 (58.1) .08
SF-36 physical, mean (SD) 38.4 (8.2) 39.8 (7.0) 38.7 (7.9) .33
SF-36 mental, mean (SD) 48.4 (9.8) 49.9 (9.1) 48.7 (9.6) .32
SOM, Sphincter of Oddi manometry; SD, standard deviation; CSQ-CAT, Coping Strategies Questionnaire–Catastrophizing Scale; MINI, Mini 
International Neuropsychiatric Interview; RUQ, right upper quadrant; RAPID, recurrent abdominal pain intensity and disability.
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TABLE 3
Prevalence of candidate baseline predictors in patients with and without abnormal biliary manometry
Abnormal findings on
bSOM (n = 97, 53%)
Normal findings on
bSOM (n = 85, 47%)
Total sample
(N = 182) P value
Demographic factors and laboratory tests
 Sex, % female 92 92 92 .99
 Age, y, mean (SD) 39 (10.0) 37 (11.0) 38 (10.5) .11
 Elevated amylase, % 1 2 2 .60
 Elevated lipase, % 5 5 5 1.00
 Liver enzyme abnormalities, % 8 7 8 .76
Gallbladder details
 Gallstones at cholecystectomy, % 51 44 47 .37
 Abnormal nuclear scan before cholecystectomy,
 no. (%)
48 (of 58) 59 (of 54) 54 (of 112) .39
 Years since cholecystectomy, mean (SD) 4.8 (6.0) 4.1 (4.9) 4.5 (5.5) .41
 Days of pain response after cholecystectomy,
 median (min, max)
61 (0, 14,965) 31 (0, 7300) 61 (0, 14,965) .33
Functional/psychological comorbidity
 Irritable bowel syndrome, Rome III, % 43 44 43 .97
 Functional abdominal pain (Rome III), % 16 20 18 .42
 Abnormal gastric emptying study, no. (%) 12.5 (16) 5 (19) 9 (35) .58
 Catastrophizing score (CSQ-CAT), mean (SD) 6.8 (6.5) 8.6 (6.9) 7.6 (6.8) .05
 MINI depressive disorder, % 6 11 8 .28
 MINI anxiety disorder 6 14 10 .07
Pain pattern, disability, quality of life
 RUQ pain only, % 44 41 43
 Central epigastric pain only, % 11 12 11.5 .91
 Both RUQ and epigastric pain, % 44 47 46
 Epigastric pain worsened by meals, no. (%) 58 (62) 57 (58) 58 (120) .78
 Daily discomfort for the past month, % 55 46 51 .27
 Narcotic use, % 25 32 28 .29
 Days taking narcotics, mean (SD) 34 (27.9) 34 (28.3) 34 (27.8) .85
 RAPID score (pain-related disability), mean (SD) 91.0 (56.3) 86.6 (62.4) 89.0 (59.1) .36
 SF-36 physical, mean (SD) 38.4 (8.6) 39.8 (7.1) 38.6 (7.9) .78
 SF-36 mental, mean (SD) 48.5 (9.9) 48.4 (9.5) 48.4 (9.7) .88
bSOM, Biliary sphincter of Oddi manometry; SD, standard deviation; CSQ-CAT, Coping Strategies Questionnaire–Catastrophizing Scale; MINI, 
Mini International Neuropsychiatric Interview; RUQ, right upper quadrant; RAPID, recurrent abdominal pain intensity and disability.
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